Earnest Partners LLC raised its position in Becton Dickinson and Co (NYSE:BDX) by 83.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 123,584 shares of the medical instruments supplier’s stock after acquiring an additional 56,320 shares during the period. Earnest Partners LLC’s holdings in Becton Dickinson and were worth $26,454,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Zions Bancorporation raised its holdings in shares of Becton Dickinson and by 23.7% in the 3rd quarter. Zions Bancorporation now owns 10,718 shares of the medical instruments supplier’s stock worth $2,100,000 after buying an additional 2,050 shares in the last quarter. SevenBridge Financial Group LLC raised its holdings in shares of Becton Dickinson and by 5.2% in the 3rd quarter. SevenBridge Financial Group LLC now owns 12,579 shares of the medical instruments supplier’s stock worth $2,465,000 after buying an additional 622 shares in the last quarter. Cigna Investments Inc. New raised its holdings in shares of Becton Dickinson and by 11.8% in the 4th quarter. Cigna Investments Inc. New now owns 9,741 shares of the medical instruments supplier’s stock worth $2,085,000 after buying an additional 1,025 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Becton Dickinson and by 6.0% in the 4th quarter. BlackRock Inc. now owns 18,811,302 shares of the medical instruments supplier’s stock worth $4,026,750,000 after buying an additional 1,071,288 shares in the last quarter. Finally, Macquarie Group Ltd. raised its holdings in shares of Becton Dickinson and by 17.5% in the 3rd quarter. Macquarie Group Ltd. now owns 93,453 shares of the medical instruments supplier’s stock worth $18,312,000 after buying an additional 13,900 shares in the last quarter. 83.37% of the stock is owned by hedge funds and other institutional investors.
A number of brokerages have recently issued reports on BDX. BMO Capital Markets began coverage on Becton Dickinson and in a report on Monday, March 5th. They issued a “market perform” rating and a $249.00 target price for the company. Zacks Investment Research cut Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Tuesday, March 6th. Evercore ISI began coverage on Becton Dickinson and in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $245.00 target price for the company. Piper Jaffray Companies reissued an “overweight” rating and issued a $260.00 target price (up from $223.00) on shares of Becton Dickinson and in a report on Tuesday, February 6th. Finally, Argus increased their price target on Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a research report on Thursday, December 14th. They noted that the move was a valuation call. Six equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $238.00.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, topping the Zacks’ consensus estimate of $2.41 by $0.07. The business had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. Becton Dickinson and’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the prior year, the company earned $2.33 EPS. analysts anticipate that Becton Dickinson and Co will post 10.94 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be given a $0.75 dividend. The ex-dividend date of this dividend is Thursday, March 8th. This represents a $3.00 dividend on an annualized basis and a yield of 1.34%. Becton Dickinson and’s payout ratio is 229.01%.
In other Becton Dickinson and news, VP John E. Gallagher sold 5,346 shares of the stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $226.08, for a total value of $1,208,623.68. Following the transaction, the vice president now directly owns 9,391 shares in the company, valued at approximately $2,123,117.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Timothy M. Ring sold 269,661 shares of the stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total value of $58,737,559.02. Following the completion of the transaction, the director now owns 295,753 shares in the company, valued at $64,420,918.46. The disclosure for this sale can be found here. Insiders sold a total of 279,231 shares of company stock worth $60,895,317 over the last quarter. Corporate insiders own 1.00% of the company’s stock.
Becton Dickinson and Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.